Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib-Reference-Cited by-同舟云学术

Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib

Published:2017-02-07 Issue:12 Volume:123 Page:2268-2273
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Jain Preetesh¹,Thompson Philip A.¹,Keating Michael¹,Estrov Zeev¹,Ferrajoli Alessandra¹,Jain Nitin¹,Kantarjian Hagop¹,Burger Jan A.¹,O'Brien Susan²^ORCID,Wierda William G.¹

Affiliation:

1. Department of Leukemia; The University of Texas MD Anderson Cancer Center; Houston Texas

2. Chao Family Comprehensive Cancer Center; University of California-Irvine; Orange California

Funder

Pharmacyclics, Inc.

the Leukemia & Lymphoma Society

National Cancer Institute

The University of Texas MD Anderson Cancer Center Moon Shot Program in chronic lymphocytic leukemia

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference15 articles.

1. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study;Burger;Lancet Oncol.,2014

2. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia;Maddocks;JAMA Oncol.,2015

3. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib;Jain;Blood.,2015

4. Ibrutinib for relapsed/refractory CLL: a UK and Ireland analysis of outcomes in 315 patients;UK CLL Forum;Haematologica.,2016

5. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience;Mato;Blood.,2016

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oncogenic MTOR Signaling Axis Compensates BTK Inhibition in a Chronic Lymphocytic Leukemia Patient with Richter Transformation: A Case Report and Review of the Literature;Acta Haematologica;2024-02-24

2. Richter's transformation: Transforming the clinical landscape;Blood Reviews;2023-12

3. Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia;Leukemia & Lymphoma;2023-10-23

4. Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences;Targeted Oncology;2023-09

5. Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study;Clinical Lymphoma Myeloma and Leukemia;2023-07